SGMO (STOCKS)
Sangamo Therapeutics, Inc. Common Stock
$0.258200
+0.007000 (+2.79%)
Prev close: $0.251200
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $108.02M
- Employees
- 183
- P/E (TTM)
- -0.58
- P/B (TTM)
- -6.32
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.11 | $-0.06 | -0.0488 | -79.74% |
|
Sep 2025 (Q3)
|
$-0.11 | $0.00 | -0.1102 | -55,100.00% |
|
Jun 2025 (Q2)
|
$-0.08 | $-0.13 | +0.0501 | +38.51% |
|
Mar 2025 (Q1)
|
$-0.14 | $-0.13 | -0.0067 | -5.03% |
Financial Statements
| Revenues | $39.55M |
| Benefits Costs and Expenses | $163.05M |
| Costs And Expenses | $163.05M |
| Operating Expenses | $160.79M |
| Research and Development | $112.67M |
| Other Operating Expenses | $48.12M |
| Operating Income/Loss | -$121.24M |
| Income/Loss From Continuing Operations After Tax | -$122.93M |
| Income/Loss From Continuing Operations Before Tax | -$123.50M |
| Income Tax Expense/Benefit | -$568.00K |
| Net Income/Loss | -$122.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$122.93M |
| Net Income/Loss Available To Common Stockholders, Basic | -$122.93M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.44 |
| Diluted Earnings Per Share | -$0.44 |
| Basic Average Shares | 280,193,000 |
| Diluted Average Shares | 280,193,000 |
| Assets | $59.75M |
| Current Assets | $35.83M |
| Noncurrent Assets | $23.92M |
| Fixed Assets | $11.04M |
| Other Non-current Assets | $12.87M |
| Liabilities | $74.01M |
| Current Liabilities | $42.47M |
| Accounts Payable | $14.44M |
| Other Current Liabilities | $28.03M |
| Noncurrent Liabilities | $31.55M |
| Equity | -$14.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$14.27M |
| Liabilities And Equity | $59.75M |
| Net Cash Flow From Operating Activities | -$97.21M |
| Net Cash Flow From Operating Activities, Continuing | -$97.21M |
| Net Cash Flow From Investing Activities | -$102.00K |
| Net Cash Flow From Investing Activities, Continuing | -$102.00K |
| Net Cash Flow From Financing Activities | $70.75M |
| Net Cash Flow From Financing Activities, Continuing | $70.75M |
| Exchange Gains/Losses | $4.09M |
| Net Cash Flow | -$22.47M |
| Net Cash Flow, Continuing | -$26.56M |
| Comprehensive Income/Loss | -$116.87M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$116.87M |
| Other Comprehensive Income/Loss | -$116.87M |